1225601

Doxercalciferol

United States Pharmacopeia (USP) Reference Standard

• Sinónimos: (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1α,3β-diol, (5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol, 1α-Hydroxyergocalciferol, 1α-Hydroxyvitamin D₂, 1α-OHD2, 1-α-Hydroxyvitamin D2, 1-Hydroxyergocalciferol, TSA 840
• Fórmula empírica (notación de Hill): C₂₈H₄₄O₂
• Número de CAS: 54573-75-0
• Peso molecular: 412.65
• Número MDL: MFCD00871065
• Código UNSPSC: 41116107
• ID de la sustancia en PubChem: 329749675
• NACRES: NA.24

Propiedades

• grado: pharmaceutical primary standard
• familia API: doxercalciferol
• fabricante / nombre comercial: USP
• aplicaciones: pharmaceutical (small molecule)
• formato: neat
• cadena SMILES: CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C(\CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C
• InChI: 1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m0/s1
• Clave InChI: HKXBNHCUPKIYDM-CGMHZMFXSA-N
• Información sobre el gen: human ... VDR(7421)

Descripción

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including MSDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Doxercalciferol USP reference standard for use in specified quality tests and assays.

Also used to prepare standard, and standard stock solutions for the assay, and impurity analysis in Doxercalciferol by Liquid chromatography in conjunction with UV detector according to the United States Pharmacopeia monograph (USP).

Acciones bioquímicas o fisiológicas

Doxercalciferol is a Vitamin D2 analogue, a Vitamin D Receptor Activator (VDRA). Doxercalciferol acts as a pro-hormone, needing 25-hydroxylation in the liver for bioactivation into 1α, 25-hydroxyvitamin D2. Pivotal studies in adults on dialysis have demonstrated control of secondary hyperparathyroidism that is superior to placebo therapy, without undue suppression of 1st IMA-PTH < 300 pg/mL, or occurrences of hypercalcemia. Doxercalciferol has been shown to be effective in controlling secondary hyperparathyroidism of adult patients with CKD stages 3-4.

Doxercalciferol is a vitamin D₂ analog that acts as a pro-hormone, activated in the liver to 1α,25-dihydroxyvitamin D₂. Despite its relatively low affinity for the vitamin D receptor (VDR) (before activation), it is effective at suppressing expression of the parathyroid hormone (PTH) gene, and appears to act through the VDR.

Nota de análisis

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Otras notas

Sales restrictions may apply.

Información de seguridad

• Pictogramas: GHS06
• Palabra de señalización: Danger
• Frases de peligro: H300
• Consejos de prudencia: P264 - P270 - P301 + P310 - P405 - P501
• Clasificaciones de peligro: Acute Tox. 1 Oral
• Código de clase de almacenamiento: 6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials
• Clase de riesgo para el agua (WGK): WGK 3
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable